RecruitingNot Applicable

Establishment of a Cohort of Patients With Sepsis-associated Encephalopathy (SAE)

China3,000 participantsStarted 2021-02-01

Plain-language summary

In this study, the researcher involved the sepsis patients(defined by sepsis 3.0) in Peking Union Medical College Hospital. The SAE was defined as the Glasgow Coma Scale (GCS) score of less than 15 and the Non-SAE group GCS = 15. The control group was the non-infectious patients with acute disease strikes and the healthy control. After the sample collection, the RNA-sequence, metabolites and cytokines were under detection.

Who can participate

Age range18 Years – 89 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. sepsis 3.0 diagnostic criteria;
✓. Estimated length of hospital stay\> 24h;
✓. ages 18-89;
✓. Acute brain dysfunction: delirium, coma, epilepsy, focal neurological deficit;
✓. Patients who meet the non-infectious SIRS diagnostic criteria

Exclusion criteria

✕. Diagnosis of patients with brain injury before admission, including Alzheimer's disease, craniocerebral injury, etc .;
✕. Primary brain injury (cerebral hemorrhage, cerebral infarction, etc.), secondary brain injury (liver brain, lung brain, uremia encephalopathy, pancreatic encephalopathy, metabolic encephalopathy, Wake encephalopathy, etc.);
✕. pregnant and lactating women;
✕. Those who have undergone bypass surgery in the past 3 months;
✕. Hearing and vision impairment;
✕. mental illness and melanoma;
✕. Abnormal coagulation, active bleeding
✕. Patients with infection at lumbar puncture site

What they're measuring

Finding the pathogenesis of sepsis encephalopathy

Timeframe: 2020-2030

Trial details

NCT IDNCT04230447

SponsorYi Li, MD

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-11-01

Contact for this trial

Yi Li, Medical PhD

86-0-13693109826 billliyi@126.com

View on ClinicalTrials.gov More Sepsis-Associated Encephalopathy trials